ClinicalTrials.gg
Not yet recruitingNCT06811948Updated Feb 6, 2025

Sleep-Disordered Breathing in the Acute Phase After Stroke and Neuropsychiatric Outcomes

An observational study in Stroke, Fatigue Symptom and Obstructive Sleep Apnea, sponsored by Blekinge County Council Hospital. Not yet recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-06.

Sponsored by Blekinge County Council Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
340
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 158 studies in Stroke with a site in Sweden — 30 open to participants now, 42 under way, 5 of them phase 3. Stroke · Sweden.

Planned enrollment
15th of 35
340 · median 230
Started
2025
with 8 others
Observational
35 of 158
7 open now
Primary completion
2027-05
later than 18 of 41 live
Registered
139th of 158
by date

Among the 158 studies in Stroke with a site in Sweden, this one is the 15th largest by planned enrollment of the 35 observational ones that give a count, is one of 9 that started in 2025, is one of 35 observational ones, reaches primary completion later than 18 of the 41 other live ones, and was the 139th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

30 of the 158 studies in Stroke with a site in Sweden are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Stroke with a site in Sweden, or all of them as a file.
02

Study summary

In people who have had a stroke or a transient ischemic attack (TIA), it is common to have problems with breathing patterns during sleep, particularly a condition called obstructive sleep apnea. Another common long-term problem after a stroke is post-stroke fatigue, which affects function and quality of life after stroke. There is currently no clearly effective treatment for post-stroke fatigue. We are investigating whether there might be a connection between sleep-related breathing disturbances, and the risk of developing long-term post-stroke fatigue

The project is being conducted at Blekingesjukhuset Karlskrona, and inpatients with stroke are asked to participate. Participants are equipped with a sleep analysis pad under the mattress that measures breathing patterns during the night, as well as a wrist-worn device that measures oxygen saturation in the blood. Participants are also asked about their functional level in daily life and any symptoms of obstructive sleep apnea. One year after the stroke, participants are invited for a follow-up visit where we ask about post-stroke fatigue, depressive symptoms, and treatment and investigations related to the stroke.

We will then investigate the relationship between sleep-related breathing disturbances, measured early after stroke, and the risk of significant fatigue after the stroke. This could lead to future studies with treatment trials for obstructive sleep apnea in certain individuals with post-stroke fatigue. The study could also lead to potentially increased awareness that these conditions might be connected, which could result in a higher likelihood of detecting treatable obstructive sleep apnea in certain subgroups after stroke.

Read the detailed description

Stroke is the second leading cause of death and a common cause of acquired disability worldwide, and the burden of the disease at the societal level is expected to increase in the coming decades. Stroke can result in various long-term consequences, both neurological (such as aphasia, paresis, sensory or visual disturbances, and coordination and balance disorders) and neuropsychiatric (such as cognitive impairment, depression, and fatigue). These consequences, in turn, affect stroke survivors' physical functions, activity levels, and ability to participate in daily activities.

Post-stroke fatigue is common, with prevalence estimates ranging between 25-85%, and 40% of stroke survivors have reported it as one of their worst symptoms. Recent Swedish studies have estimated the long-term prevalence 3-5 years after stroke to be between 24-52%. Post-stroke fatigue partially overlaps with post-stroke depression, but approximately 70% of individuals with significant fatigue do not exhibit concurrent depressive symptoms . The condition is associated with poorer performance in daily activities and lower health-related quality of life. Currently, there are no specific treatments for post-stroke fatigue. Due to its high prevalence and consequences, it has recently been identified as one of the top ten priority research questions in stroke rehabilitation by the UK National Institute for Health and Care Research.

There are conflicting reports on whether traditional vascular risk factors such as hypertension, hyperlipidemia, heart disease (including atrial fibrillation), and smoking contribute to post-stroke fatigue. Obesity is associated with post-stroke fatigue, and sleep-disordered breathing (SDB) has also emerged as a potential risk factor.

Sleep-disordered breathing is prevalent after stroke, occurring in 50-70% of some populations. The dominant condition is obstructive sleep apnea syndrome (OSAS), followed by central sleep apnea. Established treatments for OSAS include continuous positive airway pressure (CPAP), mandibular advancement devices, surgical interventions, and weight loss, which can reduce daytime sleepiness. Research is ongoing regarding the extent to which treated OSAS can contribute to secondary prevention in stroke. Current American guidelines for secondary prevention provide a class 2b recommendation with moderate evidence for considering OSAS screening after stroke or transient ischemic attack (TIA).

The diagnosis is primarily made through overnight respiratory monitoring, with polysomnography being the gold standard, although it is time- and resource-intensive and may be cumbersome for the patient. Limited polygraphic examinations can also be conducted both in hospitals and at home.

Research Questions:

  1. What is the 1-year prevalence of post-stroke fatigue in a hospital-based cohort in Blekinge?
  2. How many individuals with stroke have significant sleep-disordered breathing according to non-invasive measurement?
  3. What proportion of individuals with post-stroke fatigue had significant sleep-disordered breathing during hospitalization?
  4. Can early, non-invasive, and simple measurement of sleep-disordered breathing in hospitals predict a subgroup of stroke patients who will develop significant fatigue?
  5. Is there evidence that treatment goals after stroke are achieved to a lesser extent in those with significant fatigue?
03

Conditions studied

  • Stroke
  • Fatigue Symptom
  • Obstructive Sleep Apnea
  • Sleep Disordered Breathing (SDB)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hospital-based, prospective inclusion at a single site in Karlskrona, Sweden.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • Stroke according to WHO definition (31) (ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage)
  • with MRI-verified lesions corresponding to symptoms
  • to participate

Exclusion criteria

Exclusion Criteria:

  • Traumatic stroke
  • Tumor-associated bleeding
  • Expected survival \<3 months
  • Unconsciousness (RLS >3)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
340 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Fatigue Assessment Scale

    Measurement of post-stroke fatigue at 1 year follow-up.

    Time frame: 1 year follow-up

Other outcomes

  1. Apnea-hypopnea index

    Apnea-hypopnea index measured during hospital stay with Withings Sleep Analyzer. Used as a biomarker for sleep disordered-breathing.

    Time frame: Within 72 hours of ictus

  2. Nocturnal time under 90% blood oxygen saturation

    Measured with pulse oximeter. Used as a biomarker of sleep-disordered breathing.

    Time frame: Within 72 hours of ictus

  3. Oxygen Desaturation Index

    Measure of nocturnal desaturations

    Time frame: Within 72 hours of ictus

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for May 2027, 27 months later.

Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 27 months is below that.

Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2025
First posted
Feb 6, 2025
StartEst.
Feb 20, 2025
Primary completionEst.
May 20, 2027
CompletionEst.
Dec 20, 2027
Last update
Feb 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06811948
Lead sponsor
Blekinge County Council Hospital
Responsible party
Joseph Aked (Post-doc, Resident Physician Internal Medicine, Blekinge County Council Hospital) — Principal investigator
First posted
Feb 6, 2025
Start date
Feb 20, 2025 (estimated)
Primary completion
May 20, 2027 (estimated)
Completion
Dec 20, 2027 (estimated)
Last update
Feb 6, 2025

Study contacts

Joseph Aked, MD, PhD
Contact
joseph.aked@gmail.com
0046767723725

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion